{"title":"Procept BioRobotics vs Smith+Nephew: Medical & surgical compared","url":"https://www.frontiertechintelligence.com/compare/procept-biorobotics-vs-smith-nephew","comparison":"Smith+Nephew ranks 65 on the Robotics 100 with a score of 81; Procept BioRobotics ranks 88 with 78. Smith+Nephew is ahead on firepower. Level on deployment, production, commercials, progress, technology, positioning and leverage. Procept BioRobotics is based in San Jose, United States, Smith+Nephew in Watford, United Kingdom. Procept BioRobotics: Established. Smith+Nephew: Established. Procept BioRobotics is named in 9 signals and Smith+Nephew in 2.","companies":[{"name":"Procept BioRobotics","url":"https://www.frontiertechintelligence.com/companies/procept-biorobotics","city":"San Jose","country":"United States","stage":"Established","founded":null,"last_round":null,"positioning":"Procept BioRobotics is a US surgical-robotics maker whose Aquablation system runs about 12,200 US procedures a quarter, with FY26 guidance of $390-410M (+27-33%). It gained FDA clearance for its second-generation FirstAssist AI in Q1-26, an EAU guideline recommending Aquablation over TURP, and its first UK Hydros units at ASPs above $400k. It is not yet profitable (Q1-26 net loss widened to $31.6M), with adjusted-EBITDA breakeven targeted for Q4-26.","assessed_in":{"domain":"Robotics","list":"Robotics 100","rank":88,"score":78,"tier":"member","scores":{"gate_ne":["technology","firepower"],"leverage":6,"position":8,"progress":8,"firepower":8,"commercial":8,"deployment":8,"production":8,"technology":8},"why":"Procept BioRobotics develops and sells robotic surgical systems for urologic procedures, including the AquaBeam Robotic System for waterjet ablation in benign prostatic hyperplasia treatment.","segment":"Medical & surgical","layer":"Systems"},"signals_total":9,"facts_total":2},{"name":"Smith+Nephew","url":"https://www.frontiertechintelligence.com/companies/smith-nephew","city":"Watford","country":"United Kingdom","stage":"Established","founded":null,"last_round":null,"positioning":"Smith+Nephew's CORI handheld robotic platform (within the LSE:SN group) covers revision knee, hip, and shoulder procedures in hospital and ASC settings, with CORI XT first clinical cases in June 2026 (shoulder arthroplasty at Duke Health, knee at NYU Langone). It showcased handheld robotics at AAOS 2026. CORI-specific revenue is not broken out of the group.","assessed_in":{"domain":"Robotics","list":"Robotics 100","rank":65,"score":81,"tier":"member","scores":{"gate_ne":["technology","firepower"],"leverage":6,"position":8,"progress":8,"firepower":10,"commercial":8,"deployment":8,"production":8,"technology":8},"why":"Smith+Nephew develops and sells the CORI Surgical System, a robotic-assisted platform for orthopedic surgery. Its medical robotics business qualifies as a medical and surgical robotics system.","segment":"Medical & surgical","layer":"Systems"},"signals_total":2,"facts_total":10}],"note":"Assessment by Frontier Tech Intelligence; facts and signals carry their sources."}